maral amangurbanova
@drmaralmd
@UCSDACTRI | @HarvardMed | @BIDMCHealth
ID: 216303432
16-11-2010 10:01:04
2,2K Tweet
1,1K Followers
302 Following
I am thrilled for the recent evidence in PEth testing to better classify SLD subtypes. Great presentation by Federica Tavaglione at the MetALD Conference ! Rohit Loomba Federica Tavaglione Veeral Ajmera maral amangurbanova MASLD Research Center UC San Diego Health UCSD Gastroenterology #LiverTwitter
How to innovate in MetALD clinical trials? Rohit Loomba provided relevant considerations for security and endpoints. NITs biomarkers may play a role in early phase studies! MASLD Research Center Federica Tavaglione maral amangurbanova Veeral Ajmera Mónica Tincopa MD MSc UCSD Gastroenterology #LiverTwitter MetALD Conference
Taking a different approach, we arrived at the same conclusion Nature Medicine🔥 🔵discordant pPRS (PNPLA3+): liver-specific MASLD with faster liver disease progression⚡️ 🔴concordant pPRS: cardiometabolic MASLD with increased risk of CVD🫀and diabetes🍰 👇nature.com/articles/s4159…
We are incredibly grateful for all our team members and collaborators who made 2024 possible! Rohit Loomba UCSD Gastroenterology Mónica Tincopa MD MSc Veeral Ajmera maral amangurbanova @AlexHYangMD Cynthia Hsu Nabil Noureddin Luis Antonio Díaz, MD William Alazawi Wenhao Li David Marti Aguado Daniel Huang and more!
What is the prevalence of SLD, advanced fibrosis and cirrhosis among individuals with overweight or obesity in the 🇺🇸general population? To bridge this gap in knowledge, we launched the San Diego Liver Study🔥 a large prospective study with liver MRI-PDFF and MRE Rohit Loomba 🧵👇
💡Here’s what we found👀 Among >500 community-dwelling individuals with overweight or obesity: 📈SLD 75% 📈Advanced fibrosis 11% 📈Cirrhosis 4.5% Gut Journal @AlexHYangMD Mónica Tincopa MD MSc Veeral Ajmera maral amangurbanova MASLD Research Center UCSD Gastroenterology UC San Diego Health Sciences bit.ly/4fRh0Ub
Let me take you through our recent findings on PEth🍺 in differentiating MetALD from MASLD😎👇 📌AUROC 0.81 (95%CI 0.73-0.89) 📌Optimal cut-off 25 ng/mL 🏆Superior performance vs indirect alcohol biomarkers (AST/ALT, GGT, MCV, ANI) roypounder.apt Daniel Huang doi.org/10.1111/apt.18…
Great talk by Dr. Gregory Gores on novel potential inflammatory targets for PSC, involving IL-17, at the San Diego Digestive Diseases Research Center MASLD Research Center UCSD Gastroenterology Mayo Clinic Gastroenterology & Hepatology Rohit Loomba Federica Tavaglione maral amangurbanova
This Primer on MASLD Nature Reviews Disease Primers nature includes: ▶️ Mechanisms ▶️ Genetics ▶️ Epidemiology ▶️ Risk stratification algorithms ▶️ Non-invasive tests ▶️ Therapeutic options ▶️ Clinical trial landscape Rohit Loomba UCSD Gastroenterology Yong Loo Lin School of Medicine #LiverTwitter nature.com/articles/s4157…
A post a week late, but as a first-gen Turkmen-American physician, my heart is filled with gratitude for countless blessings. Especially for my mentor Rohit Loomba, who believed in me more than I believed in myself. I’ll truly miss my MASLD Research Center family. #Match2025 #IMbound
Congratulations maral amangurbanova - I am so proud of you and look forward to seeing you reach great heights! Keep it up!
Congratulations to maral amangurbanova on matching into the Internal Medicine program at Mt. Sinai! 🙌👏Your contributions to MASLD Research Center have been invaluable. You’re destined for great things — you will be deeply missed!
